	US 12,138,255 B2
	Pharmaceutical compositions of cabozantinib
Sushant Omprakash Dube, Maharashtra (IN); Suprit Dilip Saoji, Maharashtra (IN); Pankaj Kisan Chatki, Telangana (IN); Sumitra Ashokkumar Pillai, Telangana (IN); and Girish G. Kore, Maharashtra (IN)
Assigned to SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed by SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed on May 5, 2023, as Appl. No. 18/312,857.
Application 18/312,857 is a continuation of application No. 18/108,423, filed on Feb. 10, 2023, granted, now 11,679,105.
Application 18/108,423 is a continuation of application No. 17/673,583, filed on Feb. 16, 2022, granted, now 11,590,122, issued on Feb. 28, 2023.
Claims priority of application No. 202141007078 (IN), filed on Feb. 19, 2021.
Prior Publication US 2023/0270736 A1, Aug. 31, 2023
Int. Cl. A61K 31/47 (2006.01); A61K 9/10 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 9/10 (2013.01)]

6 Claims

1. A pharmaceutical composition suitable for oral administration comprising cabozantinib in the form of an amorphous solid dispersion and at least one pharmaceutically acceptable excipient,

wherein said amorphous solid dispersion consists of

a) cabozantinib or a pharmaceutically acceptable salt thereof;

b) a pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof;

c) a pore-forming agent selected from group consisting of hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), lactose, mannitol and mixtures thereof; and

d) polyethylene glycol as a plasticizer.